ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EUR neffy® ...

neffy 1 mg is the first approved needle-free epinephrine nasal spray for children aged 4 to 30 kg, addressing severe allergic reactions. ARS Pharmaceuticals announced the FDA approval of neffy 1 mg, ...

Patients at risk for anaphylaxis as well as caregivers of children at risk preferred needle-free epinephrine, according to ...

ALK’s new data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors: Denmark Monday, March 2, 2026, 18:00 Hrs [IST] ALK, a global sp ...

Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine ...

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to ...

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from ...

Please provide your email address to receive an email when new articles are posted on . Researchers captured patient and caregiver expected anxiety and well-being with different epinephrine treatment ...